University of Barcelona

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Retrieved on: 
Saturday, December 9, 2023

The data suggest that Galapagos’ CAR-T point-of-care manufacturing platform can deliver fresh product in a median vein-to-vein time of seven days.

Key Points: 
  • The data suggest that Galapagos’ CAR-T point-of-care manufacturing platform can deliver fresh product in a median vein-to-vein time of seven days.
  • To further build a robust data package, patient recruitment of the Phase 1 dose-finding part of ATALANTA-1 is ongoing.
  • The data suggest that Galapagos’ point-of-care platform can deliver fresh product in a median vein-to-vein time of seven days.
  • Seven-day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL including Richter’s Transformation: Results from the Phase 1 Euplagia-1 Trial

Peanuts: A Low-Glycemic Food

Retrieved on: 
Wednesday, November 8, 2023

ALBANY, Ga. , Nov. 8, 2023 /PRNewswire/ -- For those who have type 2 diabetes or are trying to prevent the onset of the disease, identifying foods that are best for a daily diet is imperative. The goal is to regulate blood sugar levels and prevent sugar spikes that can damage blood vessels and lead to kidney and vision complications.

Key Points: 
  • These foods are referred to as low glycemic and can help reduce the risk of developing type 2 diabetes.
  • Peanuts have a low glycemic index of 14, and research over the years has documented their positive impact on diabetes prevention.
  • There are also dessert recipes like Healthy Peanut Butter Chocolate Bars that use peanut flour, calorie-free sweetener and peanut butter.
  • As an independent forum, The Peanut Institute is uniquely positioned to work with all segments of the food industry, the research community, academia, consumer organizations and governmental institutions.

SIGMA LITHIUM ADDS SENIOR TALENT, CONSOLIDATING ITS POSITION AMONGST GLOBAL LARGE LITHIUM PRODUCERS

Retrieved on: 
Thursday, October 26, 2023

Matthew joins Sigma Lithium from Bank of America, where he was a leading coverage research director for lithium and chemical companies over the past four years.

Key Points: 
  • Matthew joins Sigma Lithium from Bank of America, where he was a leading coverage research director for lithium and chemical companies over the past four years.
  • Sigma Lithium is also augmenting its world-class environmental team by hiring Alexandre Mattos as Environmental Director.
  • The Company continues to add experienced top talent to senior leadership roles as it becomes one of the world's largest lithium producers, consolidating its leading sustainability position.
  • Alexandre will be based at Sigma Lithium headquarters at Vale do Jequitinhonha, where he will work alongside Sigma's general managers and senior operating team.

IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs

Retrieved on: 
Wednesday, October 11, 2023

IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategic license and collaboration agreement with the University of Barcelona (UB).

Key Points: 
  • IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategic license and collaboration agreement with the University of Barcelona (UB).
  • Under this agreement, IMIDomics has licensed cutting-edge technology and expertise from UB to advance research aimed at understanding and treating IMIDs.
  • Dr. H. Daniel Perez, Chief Development Officer at IMIDomics, expressed his enthusiasm for the partnership, stating, "This collaboration marks a significant milestone for IMIDomics as we continue our relentless pursuit of novel therapies for IMIDs.
  • We believe working closely with the University of Barcelona will help us accelerate our research and ultimately benefit patients suffering from IMIDs."

New Gut Microbiome Research Points to Positive Impact on Memory and Mood from Peanut Consumption

Retrieved on: 
Tuesday, September 26, 2023

Findings from the ARISTOTLE study were published online in the Journal of Functional Foods this September and shared by The Peanut Institute .

Key Points: 
  • Findings from the ARISTOTLE study were published online in the Journal of Functional Foods this September and shared by The Peanut Institute .
  • Earlier results from the ARISTOTLE trial showed that participants who consumed peanuts and peanut butter experienced an improvement in memory and stress response, largely due to polyphenols in peanuts.
  • The new findings confirm the ability of the gut microbiota to potentially produce compounds from peanut polyphenols that can improve brain response.
  • The Peanut Institute pursues its mission through research programs, educational initiatives and the promotion of healthful lifestyles to consumers of all ages.

Higher Education Market size worth USD 853.28 Billion, Globally, by 2030 at 7.03% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, September 6, 2023

JERSEY CITY, N.J., Sept. 6, 2023 /PRNewswire/ -- The Global Higher Education Market is projected to grow at a CAGR of 7.03% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 477.12 Billion in 2022 and is expected to reach USD 853.28 Billion by the end of the forecast period.

Key Points: 
  • The report provides an in-depth analysis of the global Higher Education Market, including its growth prospects, market trends, and market challenges.
  • The global Higher Education Market, characterized by post-secondary and tertiary education institutions, is undergoing a significant transformation.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Higher Education Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Higher Education Market into Course, Institution, Mode, And Geography.

Higher Education Market size worth USD 853.28 Billion, Globally, by 2030 at 7.03% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, September 6, 2023

JERSEY CITY, N.J., Sept. 6, 2023 /PRNewswire/ -- The Global Higher Education Market is projected to grow at a CAGR of 7.03% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 477.12 Billion in 2022 and is expected to reach USD 853.28 Billion by the end of the forecast period.

Key Points: 
  • The report provides an in-depth analysis of the global Higher Education Market, including its growth prospects, market trends, and market challenges.
  • The global Higher Education Market, characterized by post-secondary and tertiary education institutions, is undergoing a significant transformation.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Higher Education Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Higher Education Market into Course, Institution, Mode, And Geography.

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

Retrieved on: 
Friday, June 9, 2023

These preliminary results will be presented today during an oral presentation at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023 ( Abstract #S222 ).

Key Points: 
  • These preliminary results will be presented today during an oral presentation at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023 ( Abstract #S222 ).
  • Epcoritamab is being co-developed by Genmab and AbbVie (NYSE: ABBV) as part of the companies' oncology collaboration.
  • Results from this study were also presented at this year’s American Society of Clinical Oncology (ASCO) Meeting on June 6, 2023.
  • The median overall survival (OS) was 18.5 months for LBCL patients and 19.4 months for DLBCL patients.

Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer

Retrieved on: 
Thursday, May 25, 2023

The company has received approval to initiate TPM502’s clinical development in a Phase 2a study based on TPM502 preclinical data and clinical results from the Phase 1 study assessing Topas’ TPC TPM203 in patients with pemphigus vulgaris.

Key Points: 
  • The company has received approval to initiate TPM502’s clinical development in a Phase 2a study based on TPM502 preclinical data and clinical results from the Phase 1 study assessing Topas’ TPC TPM203 in patients with pemphigus vulgaris.
  • “The Phase 2a study will determine the capacity of TPM502 to promote immune tolerization in celiac disease patients and will confirm the safety profile of TPCs.
  • It will also further establish the potential of the Topas platform to generate novel therapeutics for the treatment of T-cell-mediated diseases,” commented Cristina de Min, MD, Chief Medical Officer of Topas Therapeutics.
  • Mireia Gómez-Angelats, PhD, has joined as Chief Business Officer and Christian Schröter, PhD, as Chief Operating Officer, adding significant international pharmaceutical experience to Topas’ leadership as the company moves to mid-stage clinical development.

New Research Uncovers Vascular Benefits of Peanut Consumption on Young Adults

Retrieved on: 
Wednesday, April 19, 2023

The research, which was recently published in the journal Antioxidants and shared by The Peanut Institute , discusses a preventive medicine approach for younger generations.

Key Points: 
  • The research, which was recently published in the journal Antioxidants and shared by The Peanut Institute , discusses a preventive medicine approach for younger generations.
  • The six-month study conducted by the University of Barcelona involved 63 healthy young adults ages 18-33 who included a single serving of peanuts or peanut butter in their regular, daily diet.
  • "There's an urgent need to focus cardiovascular disease education and prevention efforts on young adults," says Dr. Sterling.
  • "Urinary Phenolic Metabolites Associated with Peanut Consumption May Have a Beneficial Impact on Vascular Health Biomarkers ".